Navigation Links
Hospira Launches Piperacillin and Tazobactam for Injection in the United States
Date:10/21/2010

LAKE FOREST, Ill., Oct. 21 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced the launch of piperacillin and tazobactam for injection in the United States. The medication is a generic version of Zosyn®, the world's leading injectable antibiotic, from Pfizer (Wyeth). Piperacillin and tazobactam injection posted 2009 U.S. sales of more than $855 million.

Piperacillin and tazobactam for injection is a broad-spectrum antibiotic used to treat patients with moderate to severe infections. It is an injectable combination product that consists of piperacillin (an extended-spectrum penicillin) and tazobactam (a beta-lactamase inhibitor).

"The launch of piperacillin and tazobactam for injection represents another significant generic injectable introduction for Hospira this year, furthering our goal of taking costs out of the healthcare system by providing high-quality, lower-cost alternatives to proprietary medications," said Joshua Gordon, vice president, Specialty Pharmaceuticals, Hospira.

Hospira's piperacillin and tazobactam product portfolio extends beyond the formulations available from the originator. In addition to immediately offering the injectable medication in 2.25 g, 3.375 g and 4.5 g single-dose vials, Hospira will also market the only piperacillin and tazobactam for injection in Hospira's proprietary ADD-Vantage™ system.

The ADD-Vantage ready-to-use drug delivery system from Hospira enhances customer convenience and aids patient safety by eliminating the need for needles. To help hospitals reduce medication errors, Hospira also labels all of its injectable products with unit-of-use bar codes.

Hospira currently markets the piperacillin and tazobactam combination injectables in more than a dozen markets outside the United States, with plans to expand the launch to several Asian markets in late 2010 and early 2011.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth opportunities for certain generic specialty injectable products. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Announces New Contracts in Effect with Novation for Infusion Pumps, Solutions and Equipment
2. Hospira to Host Conference Call for Third-Quarter 2010 Results
3. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
4. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
5. Hospira Announces CEO Succession Plan
6. Hospira to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference Aug. 12
7. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
8. Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections
9. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
10. Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
11. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):